Balversa (erdafitinib) — Medica
Pancreatic adenocarcinoma
Initial criteria
- age ≥ 18 years
- has fibroblast growth factor receptor (FGFR) genetic alterations
- has locally advanced, recurrent, or metastatic disease
- used for subsequent therapy
- used as a single agent
Approval duration
1 year